Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .

This is a phase III clinical study to evaluate the efficacy and safety of recombinant botulinum toxin type A(Eveotox)in adult patients with upper limb spasticity. The purpose of this study was to observe efficacy and safety of Eveotox compared with placebo in adult patients with upper limb spasticity.

Participants needed: 207
Trial details
Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: JHM BioPharma (Tonghua) Co. , Ltd.Updated: Nov 21, 2025Locations: 2
Eligibility criteria

Participant must be 18 to 80 years of age inclusive, at the time of signing the... [+4]

Previous use of any botulinum toxin within 6 months prior to screening, or plan... [+5]

Status: Recruiting

Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines

This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of Eveotox in the treatment of moderate to severe glabellar lines. The study consists of Study Part 1 (randomized double-blind controlled study) and Part 2 (open-label study). Part I is a multicenter, randomized, double-blind, single-injection, active-controlled and placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of Eveotox in the treatment of moderate to severe glabellar lines; Part 2 is an open-label study to evaluate the efficacy, safety, and immunogenicity of repeated injections of Eveotox in the treatment of moderate to severe glabellar lines.

Participants needed: 669
Trial details
Phase: Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: JHM BioPharma (Tonghua) Co. , Ltd.Updated: Sep 2, 2025Locations: 15
Eligibility criteria

Male or female subjects who are between 18 to 65 years of age [+3]

Subjects who have a history of oversensitivity to the Botulinum Toxin A type or... [+3]